UNSPSC 51142568: Rasagiline mesilate or mesylate

This classification denotes a monoamine oxidase inhibitor and antiparkinsonian agent with the molecular formula C12H13N.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LH8C2JI290, chemically known as 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (r)-, methanesulfonate but more generally known as rasagiline mesilate, which bears US NIH Compound Identifier 3052775. European Medicines Agency schedules Rasagiline mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21334.

UNSPSC 51142568 Rasagiline mesilate or mesylate is a Commodity code that nominally identifies a specific Parkinson's disease medication, but recent state and local procurement activity under this code shows a substantial mismatch: the opportunities posted show purchases of naloxone (opioid overdose reversal), direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are rasagiline. The code appears to be applied inconsistently or incorrectly across state and local procurement systems, suggesting either a classification error in how jurisdictions are tagging pharmaceutical procurements or a misalignment between the UNSPSC taxonomy and how state and local health agencies actually structure their medication and pharmaceutical supply contracts. The actual work being solicited under this code covers commodity pharmaceutical procurement, including naloxone distribution for community health initiatives, broader prescription fulfillment programs through direct manufacturer relationships, and multi-state cooperative purchasing agreements for generic medications and OTC products.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and participating jurisdictions). Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription contracting capabilities; and MMCAP's RFP S1070000015802 (posted January 20, 2026; response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with awards effective July 1, 2026. The code shows little relevant activity aligned to its nominal product scope, and procurement professionals should verify actual commodity classification before pursuing opportunities tagged to this code.